Intuniv Approval History

• FDA approved: Yes (First approved September 2nd, 2009)
• Brand name: Intuniv
• Generic name: guanfacine
• Previous name: Connexyn
• Company: Shire plc
• Treatment for: ADHD

Intuniv (guanfacine) is a nonstimulant selective alpha-2A-receptor agonist for the treatment of children and adolescents with Attention-Deficit/Hyperactivity Disorder (ADHD).

FDA Approval History for Intuniv

Date	Article
Sep  3, 2009	Shire Announces FDA Approval of Once-Daily Intuniv (guanfacine) Extended Release Tablets for the Treatment of ADHD in Children and Adolescents Aged 6 to 17
Jul 28, 2009	FDA Issues Complete Response Letter for Intuniv (guanfacine) Extended Release for the Treatment of ADHD in Children and Adolescents
Jun 21, 2007	Shire Receives Approvable Letter From FDA for Intuniv (guanfacine) Extended Release, a Nonstimulant for the Treatment of ADHD
Aug 24, 2006	Shire Announces NDA Submission of Guanfacine Extended Release for the Treatment of ADHD in Children and Adolescents

See also...

Intuniv (guanfacine) Consumer Information

Disclaimer: Every effort has been made to ensure that the information provided here is accurate, up-to-date, and complete, but no guarantee is made to that effect. Drug information contained herein may be time sensitive. This information has been compiled for use by healthcare practitioners and consumers in the United States. The absence of a warning for a given drug or drug combination in no way should be construed to indicate that the drug or drug combination is safe, effective or appropriate for any given patient. If you have questions about the drugs you are taking, check with your doctor, nurse or pharmacist.